The paper discusses the identification of a novel negative allosteric modulator of the µ-opioid receptor (µOR) through screening with a DNA-encoded small molecule library.
The US FDA extends approval for Jemperli (dostarlimab-gxly) combined with chemotherapy to all adults with advanced or recurrent endometrial cancer. It is the first immunotherapy showing overall survival benefits.
Danuglipron is an oral small molecule glucagon-like peptide-1 (GLP-1) receptor agonist. Pfizer plans to conduct dose-optimization studies in the second half of 2024.
Sitagliptin is approved by the U.S. Food and Drug Administration (FDA) for the treatment of type 2 diabetes mellitus in adults. This approval was first granted on October 18, 2006.
etrasimod (Velsipity) is FDA approved. The FDA granted its approval on October 12, 2023. This approval allows for the use of etrasimod in the treatment of adults with moderately to severely active ulcerative colitis.